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Abstract
As the use of genomic technology has expanded in research and clinical settings, issues 
surrounding informed consent for genome and exome sequencing have surfaced. Despite the 
importance of informed consent, little is known about the specific challenges that professionals 
encounter when consenting patients or research participants for genomic sequencing. We 
interviewed 29 genetic counselors and research coordinators with considerable experience 
obtaining informed consent for genomic sequencing to understand their experiences and 
perspectives. As part of this interview, 24 interviewees discussed an informed consent case they 
found particularly memorable or challenging. We analyzed these case examples to determine the 
primary issue or challenge represented by each case. Challenges fell into two domains: participant 
understanding, and facilitating decisions about testing or research participation. Challenges related 
to participant understanding included varying levels of general and genomic literacy, difficulty 
managing participant expectations, and contextual factors that impeded participant understanding. 
Challenges related to facilitating decision-making included complicated family dynamics such as 
disagreement or coercion, situations in which it was unclear whether sequencing research would 
be a good use of participant time or resources, and situations in which the professional 
experienced disagreement or discomfort with participant decisions. The issues highlighted in these 
case examples are instructive in preparing genetics professionals to obtain informed consent for 
genomic sequencing.
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Background
Genome and exome sequencing are rapidly being integrated into research and clinical 
practice in both adult and pediatric populations. Genomic sequencing can examine 
thousands of genes simultaneously, and is currently most often used to identify the genetic 
basis of single-gene, Mendelian disorders (Biesecker & Green, 2014). Recent analyses have 
estimated that exome sequencing has a diagnostic yield for rare disorders of about 25% 
(Yang, 2013; Yang, 2014). In addition to its diagnostic capability, genomic sequencing can 
also identify variants categorized as incidental or secondary findings that are unrelated to the 
indication for testing. The scope of the ethical and legal obligation that laboratory personnel 
and healthcare providers may have to return incidental findings from genomic sequencing to 
participants has been a focus of ongoing debate. In 2013, the American College of Medical 
Genetics and Genomics (ACMG) issued a policy statement stating that laboratories offering 
sequencing are obliged to seek and return to the ordering provider pathogenic or likely 
pathogenic variants in 56 genes related to conditions for which treatment or surveillance is 
expected to significantly improve patient outcomes (Green et al., 2013). The ACMG later 
amended this policy statement to acknowledge that patients should have the opportunity to 
opt out of receiving these incidental findings during the informed consent process (ACMG, 
2014).
Due to the breadth and unanticipated nature of results that may be returned, genomic 
sequencing may pose heightened challenges for obtaining informed consent relative to the 
process of informed consent for other types of genetic testing (ACMG, 2013). The ACMG 
recommends that informed consent for sequencing include information about the likelihood 
and types of results that will be returned, including incidental/secondary findings; risks and 
benefits of testing; limitations of the sequencing technology to detect pathogenic variants; 
implications of results for family members; and alternatives to sequencing for obtaining a 
diagnosis. Additionally, the ACMG notes that patients should be informed about and able to 
opt out of allowing their identifiable results to be shared in databases, and be told about 
policies regarding re-analysis of their data and the potential for re-contact (ACMG, 2013). 
Given the impossibility of summarizing every possible results scenario that could occur in 
the consent session, it has been observed that patients or participants consenting to 
sequencing are consenting to a test that has many inherent uncertainties (Hooker et al., 
2014).
Genetic counselors and other professionals working in settings offering genomic sequencing 
are tasked with conveying this voluminous and complex information to patients or 
participants and obtaining informed, voluntary consent for testing. While theoretical and 
practical guidelines have emerged (Appelbaum et al., 2014a; Appelbaum et al., 2014b; 
Ayuso et al., 2013; Bunnick et al., 2013; ACMG, 2013), little has been written about the 
specific kinds of challenges that professionals encounter when obtaining informed consent 
for sequencing. As the demand for genomic sequencing increases, case examples can be a 
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valuable teaching tool in preparing genetics professionals to obtain informed consent for this 
type of testing (Hooker et al, 2014).
There is a limited body of research examining the experiences of professionals who obtain 
informed consent for clinical testing or research participation. Professionals who consent 
patients for participation in research have reported ethical challenges because of role 
conflicts. For example, research coordinators must balance their roles as patient advocates 
vs. study advocates, and there are situations where these roles conflict (Davis et al., 2002; 
Fisher et al., 2012). The challenges of balancing these roles may be particularly pronounced 
for health professionals, such as genetic counselors, who obtain consent for research as well 
as provide clinical care (Markel & Yashar, 2004), sometimes for the same person.
In 2010, the NIH funded Clinical Sequencing Exploratory Research (CSER) projects to 
address the critical questions raised by clinical applications of genomic sequencing, 
including the development of policies and procedures for obtaining informed consent and 
returning results to families (Manolio 2014). The resulting CSER Consortium (https://cser-
consortium.org/) includes nine U01 projects and several R01 projects in the United States 
that are offering exome or genome sequencing collectively to over 3000 pediatric and adult 
patients with a variety of conditions including cancer, cardiac conditions and, 
neurodevelopmental disorders . Through the process of consenting these patients who 
become research participants, investigators in the CSER projects have gained considerable 
experience discussing sequencing with patients and obtaining informed consent for 
participation in sequencing research studies.
Scant literature exists about the content and process of informed consent for genomic 
sequencing, and less about challenges that individual providers face when offering this 
relatively new type of testing. As part of a collaborative effort between two CSER 
consortium workgroups (Genetic Counseling Workgroup and the Informed Consent and 
Governance Workgroup), we interviewed professionals who obtain informed consent for 
genomic sequencing in research and/or clinical settings to understand their experiences and 
perspectives. Here, we present some of the challenging case examples described by these 
professionals, with an aim to identifying unique issues that may be associated with 
conducting informed consent sessions for genomic sequencing.
Methods
Participants
Study participants were recruited in one of two ways. First, one of the authors contacted a PI 
or Co-PI from each of the 9 CSER U01 clinical sequencing projects, or from other projects 
included in the CSER consortium that offer genomic sequencing in a research context, to 
request names and contact information for 1–3 individuals with the most experience 
conducting informed consent sessions for their project’s study participants. Depending on 
the protocol for obtaining informed consent for each individual project, these individuals 
could be genetic counselors, physicians, or trained study coordinators. Second, the authors 
identified five large clinical centers in the United States outside of the CSER consortium 
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offering clinical genomic sequencing and contacted one genetic counselor at each center 
about participating in the project.
Recruitment and data collection
One of the study authors sent an email describing the study to all potential participants and 
scheduled a telephone interview based on the participant’s availability. Interviews were 
conducted by four of the authors using a semi-structured interview guide that was developed 
by the study team. Interview topics included: descriptions of the person’s clinical experience 
and responsibilities; the process of consenting study participants and/or patients for genomic 
sequencing; common questions, concerns, and misperceptions about genomic sequencing 
raised by patients or study participants; and challenges to obtaining informed consent. As 
part of the interview, the interviewee was asked to summarize one particularly challenging 
case involving informed consent. These cases are the focus of this report; other findings 
from this study will be reported elsewhere.
All interviews were conducted over the phone after obtaining verbal consent from the 
participant. The interviews lasted between 30 to 80 minutes. Interviews were recorded and 
all audio files were sent to a professional transcriptionist.
The study protocol was classified as exempt by the Institutional Review Board of the 
University of Pennsylvania.
Data Analysis
Study investigators read through the transcribed interviews to check for accuracy, 
completeness, and to redact any identifiable information. De-identified interview transcripts 
were imported into QSR International’s NVivo 10 software for coding and analysis. For the 
purpose of this study, we collated and examined interviewees’ challenging or memorable 
informed consent case examples to identify groups of common challenges. Interviews in 
which the participant did not share a challenging case, or where the challenge related to 
some other aspect of care or research, such as return of results, were excluded from this 
analysis. When an interviewee shared more than one case example, we included the case or 
scenario that was more specifically described. Two investigators (AT and DS) 
independently reviewed the case examples and conducted a content analysis of the primary 
challenges for each case, with high concordance between the two reviewers. The few 
discrepancies were resolved by consensus. Investigator AT then grouped challenges 
according to common themes, which were further reviewed and discussed by a subset of 
investigators (AT, DS and BB) to ensure trustworthiness. Data from these informed consent 
cases coalesced into two overarching themes.
Results
Of 35 people contacted, 29 (83%) participated in an interview. Three-fourths of interviewees 
were genetic counselors, and the remainder were research coordinators. Research 
coordinators had various educational backgrounds, from bachelor’s degrees in biology or 
psychology to master’s degrees in epidemiology, health communication, and biotechnology. 
Some research coordinators mentioned having been trained to conduct informed consent 
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sessions by or consulting with genetic counselors working on their projects, and many used 
genetic counselors as a resource on an on-going basis.
All but one interviewee shared a challenging or memorable case example. Four individuals 
were excluded from this analysis as their case examples focused on challenges related to 
return of results, rather than to obtaining consent. The analysis is based on the remaining 24 
challenging informed consent cases. Table 1 summarizes the professions, practice settings 
and experience with informed consent for genomic sequencing of these 24 interviewees.
The challenges described by the interviewees fell broadly into two domains: challenges to 
participant understanding of the content covered during the informed consent process, and 
challenges related to facilitating decision-making about undergoing genomic sequencing 
(Table II).
Challenges to Participant Understanding
General and genomic literacy—Obtaining informed consent for genomic sequencing 
involves the discussion of complex information, and some interviewees described situations 
in which they had difficulty assessing participant understanding of the information or 
tailoring their communication to the participant’s needs. For example, a genetic counselor 
described the challenge of consenting participants with varying backgrounds and levels of 
genomic literacy (the number in parentheses is the interviewee ID):
We live in a town full of engineers, and so oftentimes with some of them, you do 
get down into the weeds of genetics and science, but also we have a lot of rural 
families that come in with very limited background, and parents who only finished 
eighth grade, and it’s challenging to explain exome sequencing to that population, 
and making sure that they understand it. (04-1)
Three interviewees reported cases in which a person with high genomic literacy wanted to 
know a lot of information about the highly technical aspects of genomic sequencing. Two of 
those interviewees, both research coordinators, referred participants to their genetic 
counselor colleagues who were able to field the more complicated technical questions. The 
third, a genetic counselor, reported that while the technical questions were a challenge, she 
worried that one genetically savvy participant who had an advanced degree in molecular 
genetics was focused on the details and limitations of sequencing rather than the 
implications of results for herself and her family:
I think at least on the pre-test side if I had to guess, based on how much she was 
focusing on that, it was almost like a defense mechanism for her. You could 
already see her skepticism with any results that might come back and whether she 
would actually believe any of them because she was focused so much on the 
limitations of the technology and our interpretation…. So it was just difficult 
because I’ve never been pushed that hard on the technical aspects by a patient 
before and I was trying to just remember what were my main goals for her to walk 
away with… (20-7)
This interviewee struggled with achieving a balance between accommodating the 
participant’s informational preferences and the interviewee’s priority that the participant 
Tomlinson et al. Page 5
J Genet Couns. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
understood the potential sequencing results and their implications for herself and her family, 
rather than focusing on the technical details of the testing. Other interviewees described the 
challenges involved with tailoring their communication of complex information to 
individuals who had much lower baseline levels of genetic knowledge, as in this genetic 
counselor’s example:
I had one participant who I think stands out in my mind because he was much less 
educated than many of our participants, but really wanted to participate because he 
had a strong family history of heart disease. And he was really worried about the 
future generations in his family and he really felt like this was an opportunity for 
him to contribute something to them. And it was a real challenge for me to start 
with him. He had highlighted the consent form very carefully and he highlighted 
the word ‘genome’ and he kept saying ‘gnome’…he was like ‘What’s a gnome? 
What does that mean?... Is that in my body? Can you take it out of me?’ (05-1)
She commented that the experience of consenting that participant helped her to reflect on 
what participants needed to understand, and how she as a professional could assess their 
understanding. She described having a mental “minimal list” of points that she felt were 
important for participants to understand before consenting to the test, which included the 
breadth and relatively uncertain nature of results. She also employed the strategy of asking 
participants to explain their understanding of the information to assess their comprehension.
Even within a single family, different individuals may have different levels of education and 
comprehension of the information provided. This interviewee related her experience 
consenting a family for pediatric sequencing where the mother had trouble understanding 
the information:
So I think that the dad was hanging in there in terms of the information, but the 
mom wasn’t. At the end, she finally says, can you tell me in three words or less 
what we’re talking [about]– and I thought, oh God. You hate that when that 
happens. So I did. And she was fine with that. But it’s just, you got different people 
at different levels. And she’s trying to nurse the baby. And chaos, chaos. (10-4)
This concern speaks to the imperative that these professionals feel to adequately inform 
participants about sequencing and assess their understanding and ability to give informed 
consent. These challenges to assessing understanding, communicating with individuals at 
varying levels of literacy, and balancing the participant’s information preferences with the 
professional’s priorities were reported by interviewees from across different sites working 
with different populations.
Managing expectations—Interviewees described the importance of participants’ 
understanding the scope of the testing, including potential results and limitations of the 
testing. A few discussed challenging cases in which the participant had unrealistic 
expectations of the testing, and their need to modulate these expectations.
I felt like I needed to absolutely pour cold water on her in the sense that no matter 
what was stated, she overstated it … And she was just so far over the top with her 
own desires for information and I was having a lot of trouble getting her to hear 
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what was being said and that this was not being promised and that we could not 
figure all this out. (03-2)
For many individuals or families, sequencing is the newest and possibly the final step in 
their “diagnostic odyssey” that included previous negative genetic testing results. 
Consequently, they express considerable hope and optimism about the ability of genomic 
sequencing to yield results that will have a substantial impact on treatment. This poses 
challenges for the interviewees as reflected in this excerpt:
I think also from the other side of it is working with patients who don’t really know 
much about what it could do; they’re excited to take part in it…just making sure 
that they really understand that they’re not getting their hopes up either, they know 
that this might not do anything for them, they might not find anything that might 
give them new treatments, but people …who are very desperate because they’ve 
progressed through all the standard lines of therapy and are looking for some sort 
of miracle. I think those are definitely the most challenging because you know that 
the patients definitely have so much invested in this and not to promise anything. 
(11-3)
For these professionals, helping participants achieve realistic expectations of the testing is an 
important part of the informed consent process. Unrealistic hopes or expectations can pose a 
challenge to understanding.
Contextual factors—Some cases focused on the contextual factors that made it difficult 
to communicate with participants or to gauge their understanding. One interviewee, whose 
project involves consenting families with very ill children with cancer, remarked on the 
importance of timing the approach for informed consent so that the family can hear and 
understand the information:
The one that really taught us timing – because we did have a family and I think we 
caught them on a day where they were already getting bad news. The oncologist 
did say it was an okay thing to go ahead and talk to them but it was, I think, more 
so you might not catch them anytime soon. The mom was extremely withdrawn. 
The dad was extremely angry. And… he didn’t what to hear the consent. They just 
wanted to sign the paperwork, and of everyone, I think those are the hardest 
because you really need them to understand. (01-3)
Communication challenges were also observed when multiple family members were present 
during the session. Some projects request samples from family members who may be 
present during the consent session and have questions about the implications of results for 
themselves or other relatives. A few interviewees noted the issues involved when the 
presence of additional family members made it difficult to communicate information to the 
primary participant, as in this case:
The more challenging ones are when lots of family members are accompanying the 
participant and they have a lot of questions, too. Most of them don’t have their own 
agenda, but a lot of times if the participant has questions they want to chime in and 
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try to answer… Or they’ll ask their own personal questions … ‘I have an aunt with 
this.’ So just start taking you off track or telling their own personal stories. (10-1)
In this case, the involvement of other family members made it difficult for her to answer 
questions, and drove the session off-topic. Another interviewee described a case in which he 
felt like he was rushing during the informed consent session because of the presence of an 
uninterested family member:
There was one case where I was speaking to the wife, the patient, and the husband 
looked so bored and agitated, and wasn’t saying anything, but you could tell. And I 
felt really bad and wanted to speed things up, but then couldn’t. (11-2)
One additional contextual challenge was the occurrence of unexpected disruptions, such as 
medical complications, as experienced by this research coordinator:
I know I’ve had several where the child…something happens with their [central] 
line and it gets crazy and out of control… (01-1)
Interviewees reported that contextual factors such as these made it particularly problematic 
for them to share information with participants and feel confident that the participants 
absorbed and understood that information.
Challenges in Facilitating Decision Making
Regardless of their level of understanding of the information conveyed, patients or 
participants must make decisions about whether to participate. A second domain of 
challenging cases shared by providers involved facilitating participant decisions about 
whether to agree to sequencing. We found that genetic counselors were somewhat more 
likely than research coordinators to discuss cases involving decision-making challenges, 
particularly those related to family dynamics or consideration of the value of sequencing for 
a particular participant.
Challenging Family Dynamics—Interviewees discussed various research and clinical 
settings in which they encountered problems facilitating decisions due to complicated family 
dynamics. In pediatric settings, interviewees recounted cases in which there were 
disagreements between parents or between parents and children about agreeing to 
sequencing. Several of the pediatric sequencing sites allow parents to decide whether or not 
to learn different categories of incidental/secondary findings, and selecting which results to 
learn was sometimes a point of disagreement within families.
So that was one…the mom was just overly—I shouldn’t say ‘overly anxious,’ but 
very anxious about the testing in general, about what they might find out about 
their son, where dad really did want mostly everything back. He thought they 
would be better equipped to deal with concerns in the future if they knew what to 
expect somewhat. So I tried as best I could to figure out where each was coming 
from, try and see what similarities they had between them, what their differences in 
thinking were and work through the possible ways that the results could come back 
and see how they would feel. But then again, they ended up calling me back the 
next week and saying that they totally changed their mind. (06-3)
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Another interviewee discussed a similar case of parental disagreement about whether to 
learn certain types of information from the sequencing:
She wanted to do the sequencing and was of the opinion that she wanted the 
oncologist to have the information to be able to make decisions but she didn’t even 
want to know anything about the tumor and was basically saying ‘If we found out 
that there was something—a marker related to poor prognosis or predictor of bad 
response—I can’t…I don’t want to know that.’ And germline…like forget it. And 
the father was really like ‘I want to know everything.’ So we discussed it in the 
room and left it that they would opt out of the germline findings… I don’t know. I 
feel like those ones where people don’t agree, I find really challenging… they 
always feel a little yucky when they’re not tied up neatly with a bow. (09-3)
In each of the above cases, the interviewees guided families through discussion and brought 
out each parent’s perspective. The families also had the opportunity to reconsider their 
decisions after leaving the informed consent session. Two other cases involved disagreement 
between parents and their children who were old enough to provide assent.
I had one whose parents were very eager; very professional parents, very interested. 
And the son—he was a teenager, I don’t know that he wasn’t interested, but the fact 
that we put so much stake into what he thought of it, he ended up declining and the 
mom…we had a conversation afterwards because she really wanted him to do it, 
and said that really the fact that we even asked him was kind of the reason he said 
no. It was the first time in this whole treatment process that he’s really had a say 
and so he just exercised that because he could, not because he didn’t really care so 
much about the results or getting them. (01-2)
And the child was adopted and there was his adopted relative and he actually 
declined to learn any incidental findings unrelated to the cancer diagnosis and his 
adopted mother actually wanted to receive those incidental findings. So, it was an 
interesting opportunity to use some of our counseling and facilitating decision-
making skills to understand what were the reasons why the child did not want the 
results? What were the reasons the parent did want the results? And is there a way 
that we could reach an agreement about what to do with those kinds of findings? So 
it wasn’t challenging, but what it did show to me is that genetic counselors are 
especially skilled. It’s what we do every day outside of the research setting is 
actually opening up the doors and facilitating that decision making, making sure 
that people understand what are the pros and cons and what’s the best way to get to 
a place where everybody is comfortable with the decisions being made. (09-2)
Interviewees (all genetic counselors) who described memorable cases involving family 
disagreement generally felt that those cases particularly evoked – or challenged – their 
counseling skills. While issues related to family disagreement were most commonly 
discussed by interviewees in pediatric settings, adult settings could also be challenging when 
multiple family members with different perspectives were present. One interviewee shared a 
case in which an adult woman who, though cognitively intact, was reliant on her family for 
transportation and medical care. The session where she was making decisions about learning 
incidental findings was also attended by her father, who was a healthcare professional and 
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well versed in genetics. The interviewee described her concern that the power dynamics in 
the session were such that the daughter might not be making her own decision about 
incidental findings.
And we started talking about that and dad says ‘Well I’ll tell you right now, she 
wants everything.’ So I had to physically move my chair and look the woman in the 
face and say ‘So it sounds like you all have maybe talked about this before coming 
in,’ and she nodded her head at me. And I said, ‘Well what were your thoughts 
about it?’…like really had to purposely engage the participant because their 
dynamic was just that dad was the decision maker. I don’t think that’s wrong…we 
talked about it, we debriefed it—me with other counselors—because all of us make 
decisions in different ways and some of us get advice from people in our family 
that we think have unique expertise and I do think the daughter felt that dad as a 
physician did have some insight into this. But it was really clear that had she not 
wanted that information, I think she still would have ended up requesting it because 
dad wanted it so much. (10-2)
The interviewee went on to observe that it was challenging to balance her concern for the 
daughter’s autonomy with respect for the way that decisions are made in the family. This 
theme was common among those cases that involved family disagreements.
Is sequencing worth it?—Two interviewees discussed cases in which patients 
questioned whether their participation in sequencing research would be a good use of their 
time or resources. Because patients at some sites are very ill with terminal conditions, 
participation in sequencing research may require a lot of time or energy and be unlikely to 
yield direct benefit. In the following case, the interviewee expressed strong feelings about 
whether a patient should participate in sequencing research due to health and logistical 
challenges:
I had one lady who was moving—she’s 31 and has colon cancer and was here 
house-sitting or something and then she’s moving to [City] the next week and … 
she really wanted to be in the study. And she wanted to fly back to [Study site’s 
city] to do her return visits and clearly, she didn’t have the resources to do that… I 
was struggling with ‘I don’t want to tell her not to do it’, but she was one where I 
was like, ‘This is actually what we’re finding for this and I can’t tell you this will 
be helpful; it hasn’t been helpful for anybody so far.’ So I think I was more frank 
with her than I am with other people because I was really like ‘this is not a good 
use of your time; you need to establish care where you’re going and not deal with 
this’. But I didn’t want to dissuade her; I don’t want to make her feel like it’s less 
of a good idea than I make it seem to other people. (03-1)
The challenge for this interviewee was in balancing her own feelings about whether 
participation was useful or feasible for the patient with respect for the patient’s choice to 
participate. A second interviewee, who also works with terminally ill patients, described a 
session that was particularly memorable:
And at the time when we met her, it was widely metastatic disease. And we knew 
that she may not live a long time. So it was memorable because it evolved from 
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informed consent into discussion about life, everybody’s interests, how we deal 
with difficulties, how we deal with diagnosis, how hopeful it was for them to be 
able to participate into something that is beyond just their own little world. (10-3)
The interviewee elaborated that she found sessions in which quality of life issues and larger 
questions leading to careful consideration of the benefits and costs of sequencing 
particularly memorable and fulfilling for her as a genetic counselor.
Interviewee discomfort with participant decisions—A few interviewees shared 
cases in which they found themselves uncomfortable with, or even distressed by, a 
participant’s decisions during the informed consent session. One interviewee recalled a case 
in which she was concerned that the participant did not have adequate time to consider his 
decision about participation.
So I was going to meet with this participant and it was after hours—it was like after 
five o’clock—and they called me up and they said ‘…He missed his enrollment 
appointment, but are you available to still see him? He’s about to get on a plane to 
go home.’ So I ran over and I sat down with him and I went over the consent form 
with him, and his wife was present… he had seen the consent form before; he had 
gone over it; …but having his wife in the room, I think, changed his perspective 
quite a bit. So he ended up enrolling….and I said ‘You know, you don’t need to 
sign this now.’ So he was fine with it. His wife was making some noises; like she 
didn’t feel so good about it. But I said ‘You don’t need to sign this now. You can 
go home. We’ll be enrolling throughout the next year or so; we’ll catch you at your 
next visit—that’s fine.’ But he said, ‘No, no, no. I’m here now. I want to sign it. I’ll 
sign the consent form. Take my blood. I’ll do the surveys online when I get home,’ 
etc. So I went through with it. (07-1)
The participant later contacted the study to withdraw, citing concerns about insurance 
discrimination. In this case, the interviewee had misgivings about whether the participant 
was making an unpressured, autonomous decision to enroll given the time constraints. She 
had told the participant that he could take his time and enroll on a future visit, but allowed 
him to enroll that day despite her concerns about time pressures. The interviewee said that 
the case influenced her future informed consent sessions in that she made sure to allow 
adequate time to avoid pressured situations.
Other cases represented situations in which the interviewee’s and participant’s perspectives 
differed considerably. One interviewee, who worked on a study that returned all incidental 
findings to participants, shared a case in which a participant was concerned about the 
possibility of learning about risk for ALS. The interviewee reflected that she needed to be 
particularly mindful not to influence the participant’s decision despite knowing that there 
was such a small likelihood of the patient receiving that type of incidental result.
It was hard because I knew that learning about ALS was very, very, very, very 
unlikely and we were having this whole big conversation about it, about something 
that probably won’t happen. It would be different if it was a likely scenario and we 
could talk about that, but it seems like a pretty far realm of possibility based on 
how our report is. And so it was hard to …adequately educate the person about it, 
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but then also being careful not to influence him, based on the fact that it was 
probably not going to happen. (07-3)
The interviewee elaborated that the participant in this case eventually declined to participate, 
which she felt was an appropriate decision given his concerns. In another case, a mother 
requested that researchers withhold information about previous research participation from 
her participating child:
So I would say that the parent I mentioned before who did not want us to assent her 
child because she didn’t want us to talk to him about the original study and explain 
what that study was about, which again, is not something we necessarily have to 
say, but it’s…she wanted us to agree that we would not mention the original study, 
which crosses a bit of a line. So that was an interesting conversation and that was 
certainly memorable. (02-1)
In this case, the researchers felt uncomfortable with this mother’s decision and explained 
that they could not comply with her request. As a result, the family declined to participate in 
the research study.
Discussion
In this study, we interviewed professionals who likely are among the most experienced in 
the United States at obtaining informed consent for genomic sequencing. Through their 
recounting of their most memorable or challenging cases, we have highlighted potential 
issues for professionals working in genetics as sequencing technology becomes more 
commonplace. Though their circumstances of sequencing and practice settings vary, the 
challenges encountered by these professionals fall broadly into two categories: ensuring 
understanding of information conveyed during the consent process, and facilitating decisions 
about testing.
Given that disclosure of information about procedures, risks, benefits and alternatives; 
participant comprehension of that information; and voluntary participation are essential 
elements of informed consent (Belmont Report, 1979), it is unsurprising that these case 
examples highlighted concerns about participant understanding of sequencing or the 
voluntariness of decisions. It has been recommended that an informed consent process for 
sequencing should include a discussion about the types of results available and their 
implications for the participant and family members, the likelihood of obtaining certain 
results, and the limitations of the testing (ACMG, 2013). Cases in which the participant had 
a low literacy level and appeared to struggle to understand information presented in the 
informed consent session were challenging for interviewees. This concern aligns with 
empirical work from other fields documenting frequent misperceptions and deficits in 
understanding among participants consenting for participation in clinical research studies, 
especially among subjects with less education (Joffe et al., 2001; Kripalani et al., 2008). A 
recent systematic review found that simplified consent forms and extended consent 
discussions significantly improve participant understanding after informed consent for 
research (Nashimura et al., 2013), and similar approaches to enhancing understanding or 
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increasing deliberation should be evaluated with respect to informed consent for genomic 
sequencing.
As acknowledged by some of the study interviewees, the complexities and uncertainties of 
genomic information are likely to create even more challenges to the informed consent 
process, especially among populations with low genomic literacy. Informed consent sessions 
will need to be carefully tailored to meet the personal needs of each patient or research 
participant through an open exchange with the patient aimed at identifying individual 
misperceptions, preferences and concerns (Hooker 2014). To supplement face to face 
counseling, innovative approaches to provide education and support decision-making are 
being developed and evaluated (Bradbury 2014; Hurle 2013), including e-leaning 
approaches (Birch 2014). To address the challenge of adequate understanding, consensus 
about what participants should understand, and at what level of detail is needed (Bradbury 
2014). Beskow et al (2014) has shown recently how through the use of a Delphi process, the 
views of multiple stakeholders can used to develop consensus on critical elements of 
informed consent.
Interviewees also highlighted the challenges of working with participants with extremely 
high expectations for diagnostic results from sequencing, which are out of alignment with 
published estimates of sequencing diagnostic yield (Yang et al., 2014). Interviewees 
responded to this challenge by directly addressing these unrealistic expectations. Previous 
research has found that the public tends to overestimate the benefits of genomic sequencing, 
particularly for diagnostic applications (McGowan et al., 2013; Wade, Tarini & Wilfond, 
2013). Public education addressing genomics generally and the limitations of genomic 
testing specifically may lead to more realistic expectations of genomic testing (Hurle, 2013).
Several interviewees, particularly those trained as genetic counselors, found themselves 
challenged by situations involving family discord, coercion or disagreement in decision 
making. Because genomic sequencing results impact families, and because the testing is 
often offered in settings where multiple family members are involved in the decisions, it can 
be challenging for professionals to navigate among competing interests. Our findings 
suggest that genetic counselors may be particularly attuned to these issues relative to 
research professionals from other backgrounds. Recognizing that genomic test results also 
impact relatives, Minari et al. (2014) have suggested that a “family consent” model of 
informed consent be used. With such a model, conflicts and agenda differences among 
family members would serve as a basis for opening lines of communication within the 
family. While helping families reach consensus about decisions could sometimes be 
challenging for professionals in this study, it also speaks to their ability to effectively 
facilitate decision-making by creating an environment in which varying viewpoints could be 
shared and discussed. Given their training, genetic counselors involved with sequencing 
research may be especially well positioned to foster this kind of environment and help all 
parties understand the research process and make decisions about participation (Hooker et 
al., 2014).
Informed consent for genomic sequencing may involve many decision points, such as 
whether to participate, selection of any optional findings offered as part of sequencing, and 
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decisions about future use and storage of data; consequently, there are many opportunities 
for disagreement among parties who may participate in the decision-making process. 
Because of their training, genetic counselors obtaining informed consent for sequencing 
likely find themselves balancing professional principles of non-directiveness with the moral 
imperative to protect the autonomy of patients or their surrogates. Those obtaining consent 
in pediatric settings need to respect the perspectives and decision-making processes of 
individual families by acknowledging that the child’s role in decision-making will vary 
(Geller et al., 2003; Miller & Nelson, 2006). Interviewees occasionally found themselves 
uncomfortable when facilitating patient decisions, especially in cases where patient 
preferences were in conflict with their own personal feelings or sense of professional 
responsibility. In a few situations, genetic counselors expressed the desire to sway 
participants who had terminal conditions or considerable resource limitations away from 
participation. This was perceived to be at odds with their professional commitment to non-
directiveness, which resulted in internal struggle or distress. Interviewees reported that they 
navigated these situations as best they could, and often reflected on lessons learned for 
future consent sessions. Bernhardt et al. (2010) also found that many distressing situations 
experienced by genetic counselors arose from a sense of obligation to be non-directive in 
situations where the counselor held strong opinions about the patient’s best interests. Given 
these experiences, particular attention to the potential for role conflicts for genetic 
counselors who are involved in both patient care and research enrollment may be warranted 
(Markel & Yashar, 2004).
Limitations
Limitations of these findings stem from the small sample size and the clinical and research 
settings included, in that challenges described in some case examples are specific to the 
population consented by interviewees (e.g. adults vs. children, healthy vs. ill populations). 
Additionally, most interviewees were involved in projects focusing on the process of 
offering and evaluating genomic sequencing, and experience of these interviewees may not 
mirror usual clinical practice. Importantly, all interviewees had experience consenting 
patients or participants for sequencing in the United States, and professionals’ experiences in 
other countries may vary. Findings from this study are not meant to be generalizable. 
Nonetheless, some challenges encountered by professionals interviewed in this study, such 
as ensuring participant understanding, supporting decision-making, varying subject literacy 
and family disagreements, were commonly referenced across settings and are likely to be 
encountered broadly in both research and clinical settings.
Practice Implications
Many of the informed consent challenges reported by interviewees in this study are not 
novel and will be familiar to professionals who have consented patients for other types of 
genetic testing. However, the complexity of genomic sequencing, the variety and uncertainty 
of potential results, the broad implications of those results, and the elevated expectations of 
personal benefit from genomic sequencing create some new or amplified challenges for 
informed consent. As the field begins to recognize informed consent challenges unique to or 
heightened by genomic technology, case examples may be a valuable training tool for 
practitioners who are new to obtaining informed consent for sequencing. These case 
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examples could be incorporated into online interactive learning modules aimed at training 
genetic counselors to provide education, facilitate decision-making and obtain informed 
consent for genomic sequencing (Hooker 2014). Issues cited by providers in these case 
examples may be a jumping-off point for preparing the genetics field to adapt existing 
techniques and consent processes to the new demands of genomic sequencing.
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Table I
Interviewees (N=24)
N %
Profession
 Research coordinator 8 33
 Genetic counselor 16 66
Years of professional experience
 0–2 6 25
 3–5 7 29
 6–10 3 13
 >10 6 25
 Not reported 2 8
Sequencing consenting experience
 CSER research only 13 54
 Non-CSER research only 1 4
 Clinical only 1 4
 Clinical and research 9 38
# patients/participants personally consented
 ≤20 2 8
 21–50 11 46
 >50 10 42
 Not reported 1 4
Population consented for sequencing
 Children only 5 21
 Adults only 11 46
 Children and adults 8 33
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Table II
Primary Challenge in Each Case
Primary Issue/Challenge Number of cases (n=24)
Challenges related to participant understanding 13
 General and genomic literacy 6
 Managing expectations 2
 Contextual factors 5
Challenges related to facilitating decision-making 11
 Challenging family dynamics 6
 Is sequencing “worth it”? 2
 Discomfort with participant decisions 3
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